SCHEMBL30079596

SCHEMBL30079596

Nc1cccnc1Nc1ccc(Cl)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.57
GRM4 Q14833 2/20 0.56
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
PDE10A Q9Y233 1/20 0.47
TNF P01375 1/20 0.44
MTOR P42345 5/20 0.41
DHODH Q02127 2/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KCNQ3 O43525 2/20 0.39
KCNQ2 O43526 2/20 0.39
TRPA1 O75762 1/20 0.39
KCNQ1 P51787 1/20 0.39
SCN5A Q14524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23927057 1.00 PIK3CA (0.57) PIK3CAGRM4CA12CA1CA2
SCHEMBL30193958 0.83 CA12 (0.53) PIK3CAGRM4CA12CA1CA2
SCHEMBL25025671 0.83 CA12 (0.53) PIK3CAGRM4CA12CA1CA2
SCHEMBL11394107 0.81 CA12 (0.62) CA12CA1CA2CA9PDE10A
Hydrochloric Acid SCHEMBL11557292 0.80 CA12 (0.60) CA12CA1CA2CA9PDE10A
SCHEMBL7695744 0.79 CA12 (0.68) CA12CA1CA2CA9PDE10A
SCHEMBL11398989 0.78 CA12 (0.62) GRM4CA12CA1CA2CA9
SCHEMBL6798468 0.78 CA12 (0.54) PIK3CACA12CA1CA2CA9
SCHEMBL6354575 0.77 PIK3CA (0.61) PIK3CACA12CA1CA2CA9
SCHEMBL29581053 0.77 CA12 (0.50) PIK3CAGRM4CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed